Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 17 Meta-analyses for duration of smoking a

From: Systematic review with meta-analysis of the epidemiological evidence in the 1900s relating smoking to lung cancer

Duration of smoking Statisticb All lung cancerc Squamousd Adenoe
Number of setsf   72 26 23
About 20 yearsg n 55 23 21
  F 2.46 (2.31-2.63) 6.46 (5.60-7.45) 2.33 (2.04-2.66)
  R 2.48 (2.09-2.95) 4.66 (3.03-7.16) 1.72 (1.20-2.46)
  H, PH 5.70, p < 0.001 6.52, p < 0.001 6.04, p < 0.001
About 35 yearsh n 39 15 12
  F 6.17 (5.80-6.55) 18.25 (15.61-21.34) 5.13 (4.43-5.95)
  R 5.90 (4.75-7.32) 14.06 (7.45-26.52) 3.53 (1.81-6.88)
  H, PH 10.39, p < 0.001 11.37, p < 0.001 15.91, p < 0.001
About 50 yearsi n 45 16 13
  F 13.46 (12.61-14.36) 26.27 (22.20-31.09) 5.24 (4.41-6.23)
  R 10.13 (7.66-13.39) 27.18 (13.36-55.28) 5.25 (2.70-10.20)
  H, PH 15.58, p < 0.001 13.13, p < 0.001 12.82, p < 0.001
Longest vs. shortestj n 76 27 23
  F 3.81 (3.62-4.02) 3.55 (3.25-3.89) 2.39 (2.09-2.72)
  R 3.56 (2.90-4.35) 3.93 (3.10-4.97) 2.64 (2.04-3.43)
  H, PH 11.48, p < 0.001 4.23, p < 0.001 3.00, p < 0.001
  1. a Within each study, results are selected in the following preference order, within each sex, for:
  2. smoking status – ever, current;
  3. smoking product – any, cigarettes (ignoring other products), cigarettes only;
  4. cigarette type – any, manufactured (with or without handrolled), manufactured only;
  5. unexposed group – never any product, never cigarettes, near equivalent (see Methods), but see also footnote j;
  6. follow-up period – longest available;
  7. lung cancer type – see notes c to e;
  8. race – all or nearest available, otherwise by race;
  9. overlapping studies – principal, subsidiary;
  10. age – whole study, widest available age group;
  11. Results are then selected for:
  12. sex - single sex results, combined sex results;
  13. adjustment for potential confounders – most available.
  14. b n = number of estimates combined, F = fixed-effect meta-analysis RR (95% CI), R = random-effects meta-analysis RR (95% CI), H = heterogeneity chisquared per degree of freedom, PH = probability value for heterogeneity expressed as p < 0.001, p < 0.05, p < 0.1 or NS (p ≥ 0.1).
  15. c All or nearest available, must include at least squamous cell carcinoma and adenocarcinoma.
  16. d Squamous cell carcinoma or nearest available, but not including adenocarcinoma.
  17. e Adenocarcinoma or nearest available, but not including squamous cell carcinoma.
  18. f Number of sets of RRs available for the key value analysis, where base for comparison is never smoked.
  19. g Category for which results are provided includes 20 years but does not include 35 years.
  20. h Category for which results are provided includes 35 years but does not include 20 or 50 years.
  21. i Category for which results are provided includes 50 years but does not include 35 years.
  22. j For this analysis only, the exposed and unexposed group have the same smoking status, product and cigarette type. There is an additional preference to select the results with least adjustment for other aspects of smoking, followed by a preference to select the results for the longest (=exposed) and shortest (=unexposed) duration smokers. Alternatively preferring results with most adjustment for other aspects of smoking gives n = 77, F = 2.67 (2.53-2.82), R = 3.00 (2.57-3.49), H, PH = 5.82, p < 0.001 for all lung cancer.